B.Riley Financial analyst Mayank Mamtani maintained a Buy rating on Madrigal Pharmaceuticals (NASDAQ:MDGL) Inc on Friday, setting a price target of $174, which is approximately 50.62% above the present share price of $115.52.
Mamtani expects Madrigal Pharmaceuticals Inc to post earnings per share (EPS) of -$3.75 for the first quarter of 2021.
The current consensus among 12 TipRanks analysts is for a Moderate Buy rating of shares in Madrigal Pharmaceuticals, with an average price target of $168.27.
The analysts price targets range from a high of $204 to a low of $123.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $0 and a net profit of -$58.79 million. The company's market cap is $1.78 billion.
According to TipRanks.com, B.Riley Financial analyst Mayank Mamtani is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 33.9% and a 57.64% success rate.
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.